Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775025 | 1.00 | ALDH1A1 (0.55) | ALDH1A1FGFR3KDRPDGFRBPDGFRA | |
| SCHEMBL346120 | 0.91 | ALDH1A1 (0.55) | ALDH1A1FGFR3KDRPDGFRBPDGFRA | |
| SCHEMBL29580471 | 0.91 | ALDH1A1 (0.55) | ALDH1A1FGFR3KDRPDGFRBPDGFRA | |
| Ammonia Solution, Strong SCHEMBL28148393 | 0.89 | ALDH1A1 (0.53) | ALDH1A1FGFR3KDRPDGFRBPDGFRA | |
| SCHEMBL15551629 | 0.83 | ALDH1A1 (0.45) | ALDH1A1FGFR3KDRPDGFRBPDGFRA | |
| SCHEMBL23651806 | 0.79 | FGFR3 (0.46) | ALDH1A1FGFR3KDRPDGFRBPDGFRA | |
| SCHEMBL621353 | 0.79 | ALDH1A1 (0.52) | ALDH1A1PDGFRBPDGFRAMAPTKDM4E | |
| SCHEMBL9912661 | 0.79 | ALDH1A1 (0.52) | ALDH1A1KDRDYRK1APIK3CGMAPT | |
| SCHEMBL14843746 | 0.79 | FGFR3 (0.54) | ALDH1A1FGFR3KDRPDGFRBPDGFRA | |
| SCHEMBL12928106 | 0.79 | ALDH1A1 (0.52) | ALDH1A1FGFR3KDRADORA3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590396-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| EP-4583874-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2025-07-16 | — | — | EP | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024062089-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
| CN-111315734-B | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2022-10-20 | — | — | US | disclosed |
| EP-1147094-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042026-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | disclosed |
| US-5696119-A | SOLID TUMORS, LEUKEMIA | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| US-5529999-A | SULFONAMIDOQUINOXALINE DERIVATIVE | ELI LILLY AND COMPANY (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0672662-A1 | Quinoxaline derivative used in the treatment of tumours | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994013647-A1 | (2-QUINOXALINYLOXY)PHENOXYPROPANOIC ACIDS AND RELATED DERIVATIVES AS ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-06-23 | — | — | WO | disclosed |
| US-RE30563-E | Preparation of benzoylureas | ELI LILLY AND COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4160834-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4133956-A | Preparation of benzoylureas | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4083977-A | Novel insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas | ELI LILLY AND COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ALDH1A1 1920/4885FGFR3 1508/4885KDR 2851/4885 |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 589/4885FGFR3 2488/4885KDR 2694/4885 |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | ALDH1A1 589/4885FGFR3 2488/4885KDR 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.